A New Delivery System for Next-Generation Cell and Gene Therapies

Posted by Maria Whitman on Thu, Apr 25, 2019

Kris Elverum of Turnstone Biologics co-wrote this blog post with Maria Whitman.

The evolution of medicines from small molecules to proteins has greatly advanced patient care, and up until now, our system of therapeutic delivery in the U.S. commercial system has been built with these therapeutics in mind. The next generation of cellular and gene therapies holds tremendous promise for patients, but only if the existing delivery system is revamped. There’s a real risk that most patients won’t benefit from these therapies as stakeholders struggle to find successful business models. In a recent article for Nature’s Gene Therapy, my industry colleague, Kris Elverum, and I take a critical look at the U.S. system and outline what needs to change to make approved cell and gene therapies accessible to patients.


>
Read More

Mastering the Emotional Side of Oncology Marketing

Posted by Maria Whitman on Thu, Jan 07, 2016

There was a time when clinical evidence—primarily efficacy, tolerability and safety—could be counted on as the most predictable basis for oncology treatment decisions. However, in recent years, my clients and I have seen non-clinical factors become increasingly important to oncologists.


>
Read More

Data Analytics Give Oncology Products Competitive Edge

Posted by Maria Whitman on Tue, Mar 24, 2015

Recent launches have proven that having a great product isn’t enough. To succeed in the oncology market, pharmaceutical and biotech companies must be able to understand performance and opportunities, and explain the difference for increasingly specific patient populations. Data has come a long way, and integrated data analytics is a powerful way to surface and interpret an oncology product’s opportunity amid brutal competition.


>
Read More